Epitalon vs SS-31
Two 'anti-aging peptides' with almost opposite evidence problems — one built on decades-old, unreplicated Russian research, the other with a real (if narrow) FDA approval its marketing rarely mentions.
Short answer
SS-31 has FDA approval and Epitalon does not, which is the main thing separating them. SS-31 is the one to look at if FDA approval matters to you, though that approval does not cover every use it is marketed for, while Epitalon is marketed for telomerase activation and life extension.
Epitalon
Epithalon
Marketed for telomerase activation and life extension, but the supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.
Full Epitalon evidence reviewSS-31
Elamipretide
A cardiolipin-binding peptide with a mostly disappointing trial history; elamipretide won a narrow, confirmation-pending accelerated FDA approval for Barth syndrome — not for the anti-aging use it's sold for.
Full SS-31 evidence reviewEpitalon vs SS-31: head to head
- FDA status / approved use
Epitalon
Not an approved drug in the US; sold as research-use-only materialSS-31
FDA accelerated approval (Forzinity, 2025) for muscle strength in Barth syndrome only; investigational otherwise- Marketed for
Epitalon
Telomerase activation, life extensionSS-31
Mitochondrial function, longevity- Outcome areas
Epitalon
Longevity / lifespan; Cellular senescenceSS-31
Mitochondrial / cellular energy; Longevity / lifespan- Evidence grade
Epitalon
Clinical dataSS-31
Clinical data- How it works
Epitalon
Claimed to activate telomerase and normalize melatonin rhythm; claims are unreplicatedSS-31
Binds cardiolipin in the inner mitochondrial membrane, supporting efficient energy production- Route and dosing
Epitalon
Injectable peptide sold in research vialsSS-31
Subcutaneous injection, 40 mg once daily- Headline human result
Epitalon
Not establishedSS-31
No benefit in the phase 3 MMPOWER-3 trial of 218 adults with mitochondrial myopathy; walk distance −3.2 meters vs placebo- Strongest evidence
Epitalon
Korkushko, Bull Exp Biol Med 2011Epitalon evidence reviewPubMed 22451889SS-31
Elamipretide (Barth), Genet Med 2024SS-31 evidence reviewPubMed 38602181- Key safety signal
Epitalon
Near-no controlled long-term human safety data; vials of unverified identity, purity, dose and sterilitySS-31
No established dosing or safety profile in healthy users- How it is obtained
Epitalon
Sold gray-market as a research chemical; no approved or legitimately compounded human productSS-31
Prescription drug
| Epitalon | SS-31 | |
|---|---|---|
| FDA status / approved use | Not an approved drug in the US; sold as research-use-only material | FDA accelerated approval (Forzinity, 2025) for muscle strength in Barth syndrome only; investigational otherwise |
| Marketed for | Telomerase activation, life extension | Mitochondrial function, longevity |
| Outcome areas | Longevity / lifespan; Cellular senescence | Mitochondrial / cellular energy; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Claimed to activate telomerase and normalize melatonin rhythm; claims are unreplicated | Binds cardiolipin in the inner mitochondrial membrane, supporting efficient energy production |
| Route and dosing | Injectable peptide sold in research vials | Subcutaneous injection, 40 mg once daily |
| Headline human result | Not established | No benefit in the phase 3 MMPOWER-3 trial of 218 adults with mitochondrial myopathy; walk distance −3.2 meters vs placebo |
| Strongest evidence | Korkushko, Bull Exp Biol Med 2011Epitalon evidence reviewPubMed 22451889 | Elamipretide (Barth), Genet Med 2024SS-31 evidence reviewPubMed 38602181 |
| Key safety signal | Near-no controlled long-term human safety data; vials of unverified identity, purity, dose and sterility | No established dosing or safety profile in healthy users |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Prescription drug |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Epitalon is marketed for telomerase activation and life extension, but nearly all the supporting science is old, small, and from one Russian lab, largely unreplicated elsewhere. SS-31 (elamipretide) has the opposite shape: a mostly disappointing broader trial history, but a genuine, narrow, confirmation-pending FDA accelerated approval for Barth syndrome — a real regulatory milestone that has nothing to do with the general anti-aging use it's sold for.
Epitalon fits if
You're reading about telomerase-activation theory specifically, understanding the evidence base hasn't been independently replicated outside one research group.
SS-31 fits if
You want the compound with an actual FDA milestone behind it, understanding that milestone applies to one rare genetic disease, not general aging.
Epitalon vs SS-31: common questions
- Is SS-31 FDA-approved but Epitalon not?
- Yes. SS-31 has FDA accelerated approval (Forzinity, 2025) for muscle strength in Barth syndrome only; investigational otherwise. Epitalon is not an approved drug in the US; sold as research-use-only material.
- Which has stronger human evidence, Epitalon or SS-31?
- Neither clearly. Both have human clinical data. The key source for Epitalon is Korkushko, Bull Exp Biol Med 2011; for SS-31, it is elamipretide (Barth), Genet Med 2024.
- What are the main safety concerns with Epitalon and SS-31?
- Epitalon has near-no controlled long-term human safety data; vials of unverified identity, purity, dose and sterility. SS-31 has no established dosing or safety profile in healthy users.
Key studies behind each
Epitalon
- Khavinson VKh, Shataeva LK, Chernova AA. (2003). Effect of regulatory peptides on gene transcription. Bull Exp Biol Med. PubMed 14666197
- Korkushko OV, Lapin BA, Goncharova ND, et al. (2007). Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. PubMed 17969590
- Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. PubMed 12937682
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. PubMed 15455129
SS-31
- Szeto HH, Liu S. (2018). Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging. Arch Biochem Biophys. PubMed 30359579
- Karaa A, Bertini E, Carelli V, Cohen BH, et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. PubMed 37268435
- Karaa A, Haas R, Goldstein A, Vockley J, et al. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. PubMed 29500292
- Reid Thompson W, Hornby B, Manuel R, Bradley E, et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. PubMed 33077895
The full evidence reviews
- Epitalon (epithalon): the honest evidence behind the telomerase and longevity claims
Marketed for telomerase activation and life extension. The supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.
Updated August 2026
- SS-31 peptide (elamipretide): benefits, evidence and approval status
An elegant mitochondrial mechanism meets a hard clinical record: a cardiolipin-binding peptide with a failed myopathy trial and a narrow, confirmation-pending Barth syndrome approval. A straight read.
Updated October 2026